Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
O'Byrne, K.
Singer, J. W.
Oldham, F. B.
Ross, H.
机构：
[1] St James Hosp, Dublin 8, Ireland
[2] Cell Therapeut, Seattle, WA USA
[3] Earle A Chiles Res Inst, Portland, OR USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70650-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [31] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
  • [32] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [33] Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer
    Comella, P
    SEMINARS IN ONCOLOGY, 2001, 28 (02) : 7 - 10
  • [34] A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Blumenschein, G
    Ludwig, C
    Thomas, G
    Tan, E
    Fanucchi, M
    Santoro, A
    Crawford, J
    Breton, J
    O'Brien, M
    Khuri, F
    LUNG CANCER, 2005, 49 : S30 - S30
  • [35] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
  • [36] ASSESSMENT OF QUALITY OF LIFE (QOL) IN PHASE III TRIALS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Adamowicz, K.
    Saad, E. D.
    Katz, A.
    Jassem, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 147 - 147
  • [37] Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Popovich, Alexander Y.
    Bondarenko, Igor N.
    Tomova, Antoaneta
    Bilynskyi, Borys T.
    Hotko, Yevhen S.
    Ganul, Valentin L.
    Kostinsky, Ippolit Y.
    Eisenfeld, Amy J.
    Sandalic, Larissa
    Oldham, Fred B.
    Bandstra, Bruce
    Sandler, Alan B.
    Singer, Jack W.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (07) : 728 - 734
  • [38] Brain metastases (BM) as the primary site of relapse in two randomized phase III pemetrexed (P) trials in advanced non-small cell lung cancer (NSCLC)
    Ortuzar, W. F.
    Pennella, E. J.
    John, W. J.
    Simms, L.
    Peng, G.
    Treat, J.
    Obasaju, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] A RANDOMIZED CLINICAL TRIAL OF PACLITAXEL LOADED POLYMERIC MICELLE AND CISPLATIN VERSUS PACLITAXEL AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lee, S. Y.
    Kim, S. Y.
    Lee, K. Y.
    Jeon, Y.
    Lee, K.
    Kim, Y.
    Kim, K.
    Lee, J. C.
    Jang, T. W.
    Yum, H. K.
    ANNALS OF ONCOLOGY, 2010, 21 : 136 - 137
  • [40] Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients.
    Belani, CP
    Perry, MC
    La Rocca, RV
    Rinaldi, D
    Gable, PS
    Tester, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 656S - 656S
12345